Listen as we discuss the power of machine learning and artificial intelligence to engage rare disease patients who could benefit from new therapies and modalities of care, thus improving their outcomes. Together with Insmed, we discuss their business needs, illustrate our approach and relay how Insmed leveraged our partnership to facilitate earlier diagnosis and help physicians understand treatment regimes. We also review how we applied aggregated learnings from Arikayce patients against a broader medical claims database and identified patients most likely to have Refractory MAC lung disease. Finally, we reveal how Insmed leverages both personal and non personal activation to educate physicians about disease states and the drug that could effectively treat this condition.
Learn how IPM.ai transforms real world data into real world insights that uncover the ideal patient and their healthcare ecosystem so pharmaceutical companies can accelerate the successful research, development and commercialization of life-savings therapies.